| Field | Specification |
|---|---|
| Target | |
| Alternative names | Protein E7; E7 |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Conjugate | |
| Purification | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes protein E7 in mus musculus papillomavirus type 1 samples.
E7 is an early oncoprotein of Mus musculus papillomavirus type 1, a mouse papillomavirus used as a model for papillomavirus infection. It pushes resting host cells from G1 into S phase so the virus can use the cellular DNA replication machinery, and it has transforming and transcription-activating activities.
| Target | Protein E7 (gene E7; UniProt D9D5K3, Mus musculus papillomavirus type 1) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Mus musculus papillomavirus type 1 |
| Form | Liquid |
| Formulation | 20 mM PBS; 50% glycerol; 0.02% NaN3 |
| Storage | Store at −20 °C for up to 12 months or 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Reactivity Notes
The supplier lists reactivity with mus musculus papillomavirus type 1. UniProt places protein E7 in the host cytoplasm and host nucleus.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
